Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NTLA 
Intellia Therapeutics Inc (NTLA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/02/2025: NTLA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
29 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $22.43
1 Year Target Price $22.43
| 18 | Strong Buy |
| 4 | Buy |
| 6 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -62.65% | Avg. Invested days 17 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/02/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 975.29M USD | Price to earnings Ratio - | 1Y Target Price 22.43 |
Price to earnings Ratio - | 1Y Target Price 22.43 | ||
Volume (30-day avg) 29 | Beta 2.11 | 52 Weeks Range 5.90 - 28.25 | Updated Date 12/2/2025 |
52 Weeks Range 5.90 - 28.25 | Updated Date 12/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.25 |
Earnings Date
Report Date 2025-11-06 | When - | Estimate -1.01 | Actual -0.92 |
Profitability
Profit Margin - | Operating Margin (TTM) -808.86% |
Management Effectiveness
Return on Assets (TTM) -28.51% | Return on Equity (TTM) -52.11% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 628233034 | Price to Sales(TTM) 16.95 |
Enterprise Value 628233034 | Price to Sales(TTM) 16.95 | ||
Enterprise Value to Revenue 10.92 | Enterprise Value to EBITDA -5.51 | Shares Outstanding 115829926 | Shares Floating 110407927 |
Shares Outstanding 115829926 | Shares Floating 110407927 | ||
Percent Insiders 4.53 | Percent Institutions 87.09 |
Upturn AI SWOT
Intellia Therapeutics Inc
Company Overview
History and Background
Intellia Therapeutics Inc. was founded in 2014 and is focused on developing CRISPR/Cas9-based therapies for genetic diseases. It has achieved milestones in in-vivo gene editing and is advancing multiple clinical programs.
Core Business Areas
- Gene Editing Therapies: Intellia focuses on developing gene editing therapies using CRISPR/Cas9 technology to treat genetic diseases in areas such as liver, lung, and hematological disorders.
- Platform Development: Intellia is also involved in advancing its CRISPR/Cas9 platform technology to improve its efficacy and safety. This includes research and development efforts focused on novel delivery methods and editing strategies.
Leadership and Structure
The leadership team includes the CEO, CFO, and Chief Scientific Officer. The organizational structure comprises research and development, clinical development, and corporate functions.
Top Products and Market Share
Key Offerings
- NTLA-2001: NTLA-2001 is an in vivo CRISPR-based investigational therapy for transthyretin (ATTR) amyloidosis. It is currently in clinical trials. Competitors include Alnylam (ALNY) and Ionis Pharmaceuticals (IONS) who offer RNAi-based therapies for ATTR amyloidosis. Market share data specifically for NTLA-2001 is unavailable as it is an investigational product in clinical trials.
- NTLA-2002: NTLA-2002 is an in vivo CRISPR-based investigational therapy for hereditary angioedema (HAE). It is currently in clinical trials. Competitors include BioCryst Pharmaceuticals (BCRX), CSL Behring and Takeda who offer treatments for HAE. Market share data specifically for NTLA-2002 is unavailable as it is an investigational product in clinical trials.
Market Dynamics
Industry Overview
The gene editing industry is rapidly growing, driven by advancements in CRISPR technology and increasing demand for novel therapies for genetic diseases. There's considerable investment and competition within the sector.
Positioning
Intellia is a leading company in the CRISPR/Cas9 gene editing field, with a strong focus on in vivo therapies. Its competitive advantage lies in its proprietary technology and strategic partnerships.
Total Addressable Market (TAM)
The total addressable market for gene editing therapies is estimated to reach billions of dollars, with potential applications in various diseases. Intellia is positioned to capture a significant share of this market through its pipeline and platform technology.
Upturn SWOT Analysis
Strengths
- Proprietary CRISPR/Cas9 technology platform
- Strong intellectual property portfolio
- Strategic partnerships with industry leaders (e.g., Regeneron)
- Advancing multiple clinical programs
- Experienced leadership team
Weaknesses
- High research and development costs
- Clinical trial risks and regulatory hurdles
- Reliance on strategic partnerships
- Limited revenue generation at this stage
Opportunities
- Expanding therapeutic applications of CRISPR/Cas9 technology
- Collaborating with academic institutions and research organizations
- Securing regulatory approvals for lead product candidates
- Developing novel delivery methods for gene editing therapies
- Addressing unmet medical needs in genetic diseases
Threats
- Competition from other gene editing companies (e.g., CRISPR Therapeutics, Editas Medicine)
- Potential safety concerns associated with CRISPR/Cas9 technology
- Changing regulatory landscape for gene editing therapies
- Patent disputes and intellectual property challenges
- Economic downturn affecting research funding
Competitors and Market Share
Key Competitors
- CRSP
- EDIT
- VERV
Competitive Landscape
Intellia faces intense competition from other gene editing companies, each with their own proprietary technologies and clinical programs. Key competitive factors include efficacy, safety, delivery methods, and intellectual property.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by increased research and development spending and strategic partnerships.
Future Projections: Future growth is dependent on clinical trial success and regulatory approvals for its lead product candidates. Analyst estimates vary widely but generally anticipate significant revenue growth upon commercialization of its therapies.
Recent Initiatives: Recent strategic initiatives include advancing clinical trials for NTLA-2001 and NTLA-2002, expanding its pipeline of gene editing therapies, and strengthening its intellectual property portfolio.
Summary
Intellia Therapeutics is a promising gene editing company with a strong CRISPR/Cas9 platform. While clinical trials have inherent risks and high R&D expenses, strategic partnerships and a solid IP portfolio provide advantages. The company's success hinges on positive trial outcomes and successful commercialization, requiring careful navigation of competitive and regulatory landscapes.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (10-K, 10-Q)
- Company website
- Analyst reports
- Press releases
Disclaimers:
The information provided is for informational purposes only and should not be construed as financial advice. Investment decisions should be based on individual risk tolerance and due diligence. Market share data is approximate and may vary based on sources and definitions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Intellia Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2016-05-06 | President, CEO & Director Dr. John M. Leonard M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 403 | Website https://www.intelliatx.com |
Full time employees 403 | Website https://www.intelliatx.com | ||
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.